Emery is the Founder and Chief Executive Officer of EAC.

Prior to EAC, Emery had a 26-year career at IBM in various research, development, manufacturing, and product management positions. This included seven years in IBM’s Biomedical Systems business unit and two years on special assignment at the New York Hospital-Cornell Medical Center on a project to reverse atherosclerosis by means of extracorporeal depletion of circulatory LDL.

Emery chaired the Industrial Liaison Committee of the American Association of Clinical Chemistry (AACC) POCT division, is a past chair of the NCCLS Subcommittee on Data Management and assisted in setting up a standardization effort for middleware data integration.

Emery specializes in corporate strategy development, portfolio and pipeline evaluation, and partnerships in life science and clinical medicine. Since 2012, he has been engaged in large clinical retrospective outcome studies in hospital acquired infections, Sepsis, and multi-drug resistant infectious organisms.

He holds a BS and MS in Physics from the South Dakota School of Mines & Technology, as well as a Private Pilot license with Instrument, Glider, and Seaplane ratings.

Troy is a 30+ year veteran of the diagnostics industry. She started her career as a laboratory technologist and then moved to the corporate environment, where she has had senior positions with leading manufacturers, including BD, Siemens, and Beckman Coulter.

Troy brings to EAC her breadth of experience in global marketing, strategy development and business management along with a broad knowledge of the IVD industry and products. She understands how companies approach decision-making and the kinds of insights needed to successfully develop, design, and commercialize new technologies.

Since joining EAC in 2016, Troy has leveraged her expertise to assist clients with product development and pricing strategies, outcome assessments, acquisitions, head-to-head performance studies and market segmentation.

Troy has a BS in Medical Technology from the University at Albany and a MS in Business from Johns Hopkins University Carey Business School.

Michelle has 20 years of experience developing and managing global research studies for clients in the diagnostics industry. Her research program designs and execution have provided critical input toward the development of new products, the enhancement of existing products, establishment of appropriate pricing structures, and brand positioning. She has organized respondent panels to collect feedback over time for product development studies and has set up systems to monitor customer satisfaction and retention rates.

Most recently, Michelle has mined extensive patient data sets to support product development and market sizing, locate hot spots of infection in hospitals and triangulate points of deterioration in patient’s health during hospital stays. She is skilled in mathematical and statistical analysis, database design and management, as well as conducting in-person interviews, moderating focus groups and developing web-based surveys.

Michelle’s areas of expertise include infection prevention, healthcare associated infections, sepsis diagnostics, infectious disease and diagnostic testing in the core lab and at the point-of-care (POC). Further, she managed and published EAC’s multi-client quantitative reports on POC testing and US based Physician Office study. Michelle received her BS from Fordham University and her MBA from Mercy College, both in New York.

Mark Hughes began his career in clinical research at the Harvard School of Public Health and progressed into immunoassay research and development for Dade Behring’s former Clinical Assay division. He has held management positions in market research and business planning at the Ares-Serono Group and Gene-Trak Systems.

Mark has more than 30 years of experience in the clinical diagnostics industry and has been with EAC since 1997. He has broad experience in characterization of in vitro diagnostic (IVD) and non-IVD market and product segments. He also has done extensive work in technology assessments, market analysis, business strategies and due diligence.

Mark has worked on a wide range of assignments for major diagnostic, pharmaceutical and start-up biotechnology companies, as well as investment banks and venture capital firms. He is often quoted in many industry publications for his insights into the IVD industry.

Mark received his BS from the University of Massachusetts at Amherst and his MBA from Duke University.